BioMérieux was created in 1963, but our roots go all the way back to the 19th century, with Marcel Mérieux, a student of Louis Pasteur. A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure is driven by an unrelenting commitment to improve public health worldwide. We specialize in:
Clinical applications: We develop and produce diagnostic solutions that help healthcare professionals quickly and reliably determine a pathology or the source of a contamination and provide them with crucial information for optimal patient care.
Industrial applications: We also apply our expertise to meeting industrial microbiology needs, building innovative, precise technologies that ensure the quality and safety of food and pharmaceutical products.
The Company is present in 45 countries and serves more than 160 countries with the support of a large network of distributors.
Beginning with Marcel Mérieux’s development of the first anti-tetanus serum over a century ago, innovation has always been at the heart of bioMérieux. This pioneering spirit continues to drive our R&D teams that combine their state-of-the-art scientific knowledge with emerging techniques and new technologies to drive progress in pathogen detection and identification.
bioMérieux develops high-performance solutions that are based on three key areas of in vitro diagnostics:
• Microbiology: we are the world leader in clinical microbiology and industrial microbiological control;
• Immunoassays: we are specialized in high medical value tests;
• Molecular biology: we are a pioneer and leader in the syndromic molecular diagnosis of infectious diseases.
Last updated : June 28, 2023